Κλινικές Μελέτες – Ελληνική Αιματολογική Εταιρεία

Menu

Σύνδεση Μέλους

Protocol No: FOCUS in CML v6

F.O.C.U.S. in CML. Real-World Evidence (RWE) in Greece in patients with Chronic Myeloid Leukemia – Chronic Phase (CML-CP) who have already received at least one dose of Imatinib 600 mg following suboptimal response or failure to Imatinib 400 mg

Start date: 02/11/2026
End date: 30/11/2027
Medical condition: CML

EudraCT / EU CT No: 2025-524793-42
Protocol No: 79635322MMY2002

A Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic use of Tocilizumab to Prevent Cytokine Release Syndrome with JNJ-79635322 (Ramantamig) administration in Participants with Relapsed or Refractory Multiple Myeloma

Start date: 01/09/2026
Medical condition: R/R MM

EudraCT / EU CT No: 2025-522267-15-00
Protocol No: MK1045-005

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Start date: 31/07/2026
Medical condition: ALL

EudraCT / EU CT No: 2025-523117-28
Protocol No: DREAMM-15

A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma

Start date: 24/07/2026
Medical condition: RRM

Protocol No: 79635322MMY3002/TRIlogy-5

A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1-3 prior lines of therapy

Start date: 17/07/2026
End date: End of 2030
Medical condition: MM

EudraCT / EU CT No: 2022-501560-17-00
Protocol No: MK1026-010

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

Start date: 02/07/2026
Medical condition: R/R CLL/SLL

EudraCT / EU CT No: 2024-516869-36-00
Protocol No: EXS73565-001

A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies

Start date: 17/06/2026
End date: Recruiting
Medical condition: CLL, DLBCL, MCL, MZL, WALDENSTROM, FL

EudraCT / EU CT No: 2025-521372-62-00
Protocol No: 79635322MMY3002

TRIlogy-5 — JNJ-79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma

Start date: 31/05/2026
End date: 08/12/2032
Medical condition: Relapsed or refractory multiple myeloma after 1–3 prior lines of therapy, including an anti-CD38 antibody and lenalidomide

EudraCT / EU CT No: 2024-517247-31
Protocol No: APG2575MG301

A Global Multicenter, Double-Blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4)

Start date: 22/04/2026
Medical condition: Untreated higher risk MDS

EudraCT / EU CT No: 2025-521314-25-00
Protocol No: KO-MEN-017

Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia

Start date: 30/03/2026
End date: 30/09/2030
Medical condition: Untreated AML